Maximo support ended. Your next move is not automatic.
IBM ended regular base support for Maximo Asset Management 7.6.1.x on September 30, 2025. For regulated life sciences manufacturers, the resulting decision involves more than selecting new software. It requires establishing a defensible path for maintaining the validated state of a GMP-impacting system.
This guide gives Operations, IT, Quality, Validation, and Metrology leaders a practical framework for evaluating five potential paths:
- Upgrade to Maximo Application Suite
- Use IBM Extended Support as a short-term bridge
- Enter IBM Sustained Support
- Engage a third-party software maintenance provider
- Migrate laterally to a different asset management platform
Rather than prescribing one answer, the guide identifies which operational profiles each path fits, where the hidden complications reside, and what evidence should inform the final decision.
Download the guide to:
- Compare all five post-EOS paths using a structured decision matrix
- Understand how MAS changes infrastructure, licensing, calibration bundling, and release management
- Evaluate the OpenShift and AppPoint implications of remaining with IBM
- Assess regulated-life-sciences alternatives using validation, calibration, deployment, and scale criteria
- Re-plan validation using current FDA CSA and GAMP 5 risk-based principles
- Model the costs and realistic timelines often missing from vendor quotations
- Build a practical 90-day evaluation and decision plan
The objective is not simply to migrate. It is to choose the forward path that best fits your operational scale, IT capabilities, validation strategy, and regulated-equipment requirements.